Premier Biomedical Inc
OTC:BIEI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Premier Biomedical Inc
Cost of Revenue
Premier Biomedical Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Premier Biomedical Inc
OTC:BIEI
|
Cost of Revenue
-$12.9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$17.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.7B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.9B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-17%
|
|
Premier Biomedical Inc
Glance View
Premier Biomedical, Inc. is a research-based company, which engages in the development and discovery of medical products. The company is headquartered in Whitefish, Montana. The company went IPO on 2012-02-23. The firm has developed a line of topical hemp oil pain relief products. The firm develops medical treatments for humans, specifically focusing on the treatment of Cancer Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer’s Disease (AD), Blood Sepsis and Viremia, Feldetrex. The firm offers eight pain relief products: 96-hour pain relief patch with 50 mg of hemp oil extract, 120 milligram (mg)/ 10 milliliter (ml) water-based roll-on applicator; 150 mg/ 30 ml oil-based pump spray applicator; 150 mg/ 2 oz. ointment; 200 mg/10 ml oil-based roll-on applicator; 500 mg/ 30 ml oil-based pump-spray applicator, and 500 mg/ 1 oz. ointment. The company offers extra-corporeal treatment of disease, PTSD treatment, anti-breast cancer drugs, hemp oil, anti-aging treatments and chemical and alcohol addiction treatment.
See Also
What is Premier Biomedical Inc's Cost of Revenue?
Cost of Revenue
-12.9k
USD
Based on the financial report for Dec 31, 2019, Premier Biomedical Inc's Cost of Revenue amounts to -12.9k USD.
What is Premier Biomedical Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
89%
Over the last year, the Cost of Revenue growth was 89%.
